SecBot SecBot
SECBOTREPLAY Home › Report › TCRX

TCRX · TScan Therapeutics reported Q2 2026 EPS of -$0.23, a 15% miss vs…

TScan Therapeutics, Inc. · PRESS-RELEASE filed Aug 12, 2026 at 07:00 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed Aug 12, 2026 at 07:00 ET

TScan Therapeutics reported Q2 2026 EPS of -$0.23, a 15% miss vs consensus of -$0.20, and revenue of $1.1M, sharply down 66% YoY from $3.1M due to timing of Amgen collaboration activities. The net loss narrowed to $30.4M from $37.0M, but cash burn remains high with cash runway only into Q2 2027, pressured by upcoming debt amortization. Positive clinical data from the Phase 1 ALLOHA study and first patient dosed in the Phase 3 ALLOHA-2 trial provide pipeline catalysts, but the financial miss and cash constraints dominate the near-term outlook.

  • Q2 2026 EPS -$0.23 vs consensus -$0.20 (15% miss)
  • Q2 2026 revenue $1.1M, down 66% YoY from $3.1M
  • Net loss $30.4M vs $37.0M YoY, but cash burn remains high
  • Cash and equivalents $100.2M, runway only into Q2 2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access